NASDAQ:AFMDAffimed Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Affimed NV Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $3.43 -0.01 (-0.29 %) (As of 08/14/2020 04:00 PM ET) Add Compare Share Today's Range$3.36Now: $3.43▼$3.4950-Day Range$3.35MA: $4.15▼$4.7352-Week Range$1.42Now: $3.43▼$4.91Volume440,412 shsAverage Volume1.18 million shsMarket Capitalization$261.50 millionP/E RatioN/ADividend YieldN/ABeta2.72 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead product candidate is AFM13, a natural killer cell (NK-cell) TandAb, which is in Phase 2a clinical study of relapsed CD30-positive lymphoma and Phase 1b clinical study of anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed Hodgkin lymphoma. The company's products include AFM24, an innate cell-engaging bispecific antibody that treats patients suffering of EGFR expressing solid tumors; AFM26, which binds to B cell maturation antigen (BCMA) for the treatment of multiple myeloma; and Trispecific Abs for the treatment of multiple myeloma. Its products also comprise AFM11, a T cell TandAb, which is in Phase 1 clinical trial in patients with relapsed CD19+ B cell malignancies, including non-Hodgkin Lymphoma and acute lymphocytic leukemia (AML); and AMV564, a CD33/CD3-specific T-cell TandAb is in Phase 1 clinical study of refractory AML. The company has license agreements with Amphivena Therapeutics, Inc., Deutsches Krebsforschungszentrum, and Xoma Ireland Limited; research funding agreement with The Leukemia & Lymphoma Society; and collaboration with Merck Sharp & Dohme B.V. It also has a clinical development and commercialization collaboration with The University of Texas MD Anderson Cancer Center to evaluate AFM13 in combination with MD Anderson's NK-cell product; and Genentech. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingAffimed has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $9.00, Affimed has a potential upside of 162.4% from its current price of $3.43.Amount of Analyst CoverageAffimed has only been the subject of 2 research reports in the past 90 days. Previous Next 2.9 Community Rank Outperform VotesAffimed has received 392 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAffimed has received 286 “underperform” votes. (Add your “underperform” vote.)Community SentimentAffimed has received 57.82% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Affimed and other stocks. Vote “Outperform” if you believe AFMD will outperform the S&P 500 over the long term. Vote “Underperform” if you believe AFMD will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAffimed does not currently pay a dividend.Dividend GrowthAffimed does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Affimed insiders have not sold or bought any company stock.Percentage Held by Institutions50.82% of the stock of Affimed is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Affimed are expected to grow in the coming year, from ($0.47) to $0.05 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Affimed is -5.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Affimed is -5.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAffimed has a P/B Ratio of 6.02. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.61 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AFMD Previous Symbol CUSIPN/A CIK1608390 Webwww.affimed.com Phone49-62-2167-4360Debt Debt-to-Equity Ratio0.01 Current Ratio2.59 Quick Ratio2.58Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$23.96 million Price / Sales10.91 Cash FlowN/A Price / Cash FlowN/A Book Value$0.57 per share Price / Book6.02Profitability EPS (Most Recent Fiscal Year)($0.56) Net Income$-36,250,000.00 Net Margins-280.35% Return on Equity-135.64% Return on Assets-43.02%Miscellaneous Employees8,406 Outstanding Shares76,240,000Market Cap$261.50 million Next Earnings Date11/17/2020 (Estimated) OptionableOptionable $3.43 -0.01 (-0.29 %) (As of 08/14/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive AFMD News and Ratings via Email Sign-up to receive the latest news and ratings for AFMD and its competitors with MarketBeat's FREE daily newsletter. Affimed (NASDAQ:AFMD) Frequently Asked Questions How has Affimed's stock price been impacted by Coronavirus? Affimed's stock was trading at $1.82 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, AFMD shares have increased by 88.5% and is now trading at $3.43. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Affimed? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Affimed in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Affimed. When is Affimed's next earnings date? Affimed is scheduled to release its next quarterly earnings announcement on Tuesday, November 17th 2020. View our earnings forecast for Affimed. How were Affimed's earnings last quarter? Affimed NV (NASDAQ:AFMD) announced its earnings results on Tuesday, August, 11th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.12) by $0.04. Affimed had a negative return on equity of 135.64% and a negative net margin of 280.35%. View Affimed's earnings history. What price target have analysts set for AFMD? 2 analysts have issued 12 month price objectives for Affimed's shares. Their forecasts range from $8.00 to $10.00. On average, they anticipate Affimed's stock price to reach $9.00 in the next twelve months. This suggests a possible upside of 162.4% from the stock's current price. View analysts' price targets for Affimed. Has Affimed been receiving favorable news coverage? News articles about AFMD stock have been trending negative on Saturday, InfoTrie reports. The research group identifies negative and positive press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Affimed earned a media sentiment score of -2.7 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View the latest news about Affimed. Are investors shorting Affimed? Affimed saw a increase in short interest during the month of June. As of June 30th, there was short interest totaling 4,890,000 shares, an increase of 160.1% from the June 15th total of 1,880,000 shares. Based on an average daily volume of 1,480,000 shares, the short-interest ratio is presently 3.3 days. View Affimed's Short Interest. Who are some of Affimed's key competitors? Some companies that are related to Affimed include Kiniksa Pharmaceuticals (KNSA), Arvinas (ARVN), Arcus Biosciences (RCUS), Constellation Pharmaceuticals (CNST), Karyopharm Therapeutics (KPTI), Theravance Biopharma (TBPH), Phathom Pharmaceuticals (PHAT), Humanigen (HGEN), Nabriva Therapeutics (NBRV), Akero Therapeutics (AKRO), I-Mab (ARQT), Enanta Pharmaceuticals (ENTA), Stoke Therapeutics (STOK), Athenex (ATNX) and Retrophin (RTRX). View all competitors. What other stocks do shareholders of Affimed own? Based on aggregate information from My MarketBeat watchlists, some companies that other Affimed investors own include Novavax (NVAX), JetBlue Airways (JBLU), Sprint (S), American International Group (AIG), Amarin (AMRN), Viking Therapeutics (VKTX), Catalyst Pharmaceuticals (CPRX), Lipocine (LPCN), Sorrento Therapeutics (SRNE) and Amicus Therapeutics (FOLD). Who are Affimed's key executives? Affimed's management team includes the following people: Dr. Adi Hoess, CEO, MD & Member of Management Board (Age 57)Dr. Florian H. M. Fischer, MD, CFO & Member of Management Board (Age 51)Dr. Wolfgang Fischer, MD, COO & Member of Management Board (Age 55)Prof. Melvyn Little, Founder & ConsultantDr. Martin Treder, Chief Scientific Officer (Age 49) What is Affimed's stock symbol? Affimed trades on the NASDAQ under the ticker symbol "AFMD." Who are Affimed's major shareholders? Affimed's stock is owned by many different institutional and retail investors. Top institutional investors include Point72 Asset Management L.P. (4.54%), FMR LLC (1.60%), Globeflex Capital L P (0.78%), Assenagon Asset Management S.A. (0.58%), Goldman Sachs Group Inc. (0.40%) and Bank of Montreal Can (0.36%). Which institutional investors are selling Affimed stock? AFMD stock was sold by a variety of institutional investors in the last quarter, including Telemetry Investments L.L.C., FMR LLC, State of Tennessee Treasury Department, New York State Common Retirement Fund, UBS Group AG, and Lindbrook Capital LLC. Which institutional investors are buying Affimed stock? AFMD stock was purchased by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Globeflex Capital L P, Assenagon Asset Management S.A., Goldman Sachs Group Inc., Aigen Investment Management LP, Vigilare Wealth Management, State Board of Administration of Florida Retirement System, and First Quadrant L P CA. How do I buy shares of Affimed? Shares of AFMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Affimed's stock price today? One share of AFMD stock can currently be purchased for approximately $3.43. How big of a company is Affimed? Affimed has a market capitalization of $261.50 million and generates $23.96 million in revenue each year. The biopharmaceutical company earns $-36,250,000.00 in net income (profit) each year or ($0.56) on an earnings per share basis. Affimed employs 8,406 workers across the globe. What is Affimed's official website? The official website for Affimed is www.affimed.com. How can I contact Affimed? Affimed's mailing address is TECHNOLOGIEPARK IM NEUENHEIMER FELD 582, HEIDELBERG 2M, 69120. The biopharmaceutical company can be reached via phone at 49-62-2167-4360 or via email at [email protected] This page was last updated on 8/15/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
